½ÃÀ庸°í¼­
»óǰÄÚµå
1620650

¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ½ÃÀå : Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - Àü¸Á(2025-2030³â)

Personalized Medicine Market by Product (Personalized Medical Care, Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), Application (Antiviral, Cardiology, Immunology), End Users - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸ÂÃãÇü ÀÇ·á ½ÃÀåÀº 2023³â 5,421¾ï ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 5,755¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 6.67% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8,520¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°³ÀθÂÃãÀÇ·á(PM)´Â °³ÀÎÀÇ À¯ÀüÀû, ȯ°æÀû, »ýȰ½À°üÀû ¿äÀο¡ ¸ÂÃá Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÇ·áÀÇ Çõ½ÅÀû Á¢±Ù¹ýÀÔ´Ï´Ù. Á¤È®ÇÑ Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ ÇʼöÀûÀÎ À¯ÀüüÇÐ, ¾à¸®À¯ÀüüÇÐ, ÷´Ü Áø´ÜÇÐÀ» Æ÷°ýÇÕ´Ï´Ù. ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ È¯ÀÚ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ¿À¹Í½º ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÀ¿ë ºÐ¾ß´Â Ç¥Àû Ä¡·á°¡ ¾Ï ȯÀÚ¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» ÁÖ´Â ¾Ï ºÐ¾ßºÎÅÍ ½ÉÇ÷°ü Áúȯ, Èñ±Í À¯Àü¼º Áúȯ¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, °¢ ºÐ¾ß´Â °³ÀÎÈ­ Á¢±Ù¹ýÀÇ ÇýÅÃÀ» ´©¸± ¼ö ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ÃÖÁ¾ »ç¿ëó·Î´Â º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸±â°ü µîÀÌ ÀÖÀ¸¸ç, ÀÌµé ¸ðµÎ PMÀ» Ȱ¿ëÇØ Ä¡·á ¼º°ú¿Í ¾÷¹« È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 5,421¾ï ´Þ·¯
ÃßÁ¤ ¿¬µµ(2024³â) 5,755¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 8,520¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 6.67%

½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ±â¼ú ¹ßÀü, R&D ÅõÀÚ, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ Á¢±ÙÀ» ÃËÁøÇÏ´Â À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© µîÀÌ ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº À¯Àüü ½ÃÄö½Ì ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦, ±âÁ¸ ÀÇ·á °üÇà¿¡ PMÀ» ÅëÇÕÇÏ´Â µ¥ µû¸¥ º¹À⼺ µîÀÇ ¹®Á¦µµ ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀ» À§ÇÑ ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ® 󸮿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» ÅëÇÕÇÏ¿© ¿¹Ãø Á¤È®µµ¿Í Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Â »õ·Î¿î ±âȸµµ dzºÎÇÏ°Ô Á¸ÀçÇÕ´Ï´Ù.

Çõ½ÅÀûÀÎ ¿¬±¸ ºÐ¾ß·Î´Â ºñ¿ë È¿À²ÀûÀÎ ½ÃÄö½Ì ±â¼ú °³¹ß, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀÌ ¾à¸®À¯ÀüüÇп¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ¿¬±¸ µîÀÌ ÀÖ½À´Ï´Ù. ±â¾÷µéÀº PM°ú ¿ø°Ý ÀǷḦ °áÇÕÇÑ µðÁöÅÐ Çコ ¼Ö·ç¼Ç¿¡ ÅõÀÚÇÏ¿© ¿ø°ÝÀ¸·Î Á¾ÇÕÀûÀÌ°í °³ÀÎÈ­µÈ Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á °æÀï·ÂÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå »óȲÀº º¹ÀâÇÏ°í ´ÜÆíÀûÀÌÁö¸¸ °­·ÂÇÑ ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº Àü·«Àû ÆÄÆ®³Ê½Ê, ±â¼ú ÅëÇÕ, ȯÀÚ Áß½ÉÀÇ ¼­ºñ½º Á¦°ø¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ½ÃÀåÀÇ Æ¯¼ºÀº ¿ªµ¿ÀûÀ̸ç, ±â¼ú ¹ßÀü°ú ±ÔÁ¦ º¯È­¿¡ µû¶ó ºü¸£°Ô ÁøÈ­Çϱ⠶§¹®¿¡ Áö¼ÓÀûÀÎ ¼ºÀå°ú °æÀï·ÂÀ» °­È­Çϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ Çõ½Å°ú ÀûÀÀÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¸ÂÃãÇü ÀÇ·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®À» °ø°³ÇÕ´Ï´Ù.

¸ÂÃãÇü ÀÇ·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ý¸í°øÇÐ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡¿Í À¯ÀüÇп¡ ´ëÇÑ ÀÌÇØµµ Çâ»ó
    • º¹ÀâÇÑ ÁúȯÀ» ´ë»óÀ¸·Î ÇÑ ¸ÂÃãÇü Ä¡·á Àü·« äÅà ±ÞÁõ
    • °³ÀθÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Á¤ºÎ Áö¿ø ¹æ¾È
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¸ÂÃãÇü ÀÇ·á µµÀÔÀÇ º¹À⼺°ú ¼÷·ÃµÈ Àη ºÎÁ·
  • ½ÃÀå ±âȸ
    • °³ÀθÂÃãÇü ÀÇ·á °³¼±À» À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß Ȱµ¿
    • °³ÀθÂÃãÇü ÀÇ·áÀÇ °¡»ó ¹× µðÁöÅÐ Àü·« äÅà °¡´É¼º
  • ½ÃÀå °úÁ¦
    • Á¦ÇÑÀûÀÎ Á¢±Ù¼º ¹× Á¤È®¼º ¹®Á¦

Porter's Five Forces: ¸ÂÃãÇü ÀÇ·á ½ÃÀåÀ» Ž»öÇϱâ À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â °³ÀÎÈ­µÈ ÀÇ·á ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» º¸¿ÏÇϰí, ÀáÀçÀû µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸ÂÃãÇü ÀÇ·á ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸ÂÃãÇü ÀÇ·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : °³ÀθÂÃãÇü ÀÇ·á½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¸ÂÃãÇü ÀÇ·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: °³ÀθÂÃãÇü ÀÇ·á ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °³ÀÎÈ­µÈ ÀÇ·á ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ¸ÂÃãÇü ÀÇ·á ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

°³ÀθÂÃãÇü ÀÇ·á ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¸ÂÃãÇü ÀÇ·á ½ÃÀå : Á¦Ç°º°

  • ¼­·Ð
  • ¸ÂÃãÇü ÀÇ·á
    • ÀÇ·á Á¤º¸±â¼ú
    • ¿ø°ÝÀÇ·á
  • ¸ÂÃãÇü ÀÇ·á Áø´Ü
    • Direct-to-consumer (DTC) Diagnostics
    • Esoteric Lab Services
    • Esoteric Lab Tests
    • Genetic Testing
  • ¸ÂÃãÇü Ä¡·á
    • À¯Àüü ÀÇ·á
    • ÀÇ·á±â±â
    • Á¦¾à
  • ¸ÂÃã ¿µ¾ç ¹× °Ç°­
    • º¸¿Ï ´ëü ÀÇ·á
    • ¼Ò¸Å ¿µ¾ç

Á¦7Àå ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ¿ëµµº°

  • ¼­·Ð
  • Ç×¹ÙÀÌ·¯½ºÁ¦
  • ½ÉÀ庴ÇÐ
  • ¸é¿ªÇÐ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ
  • Á¤½ÅÀÇ·á

Á¦8Àå ¸ÂÃãÇü ÀÇ·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼­·Ð
  • Çмú¿¬±¸±â°ü ¹× ½ÇÇè½Ç
  • ¹ÙÀÌ¿À£¦Çコ ÀÎÆ÷¸Åƽ½º ±â¾÷
  • °è¾à ¿¬±¸±â°ü
  • Áø´Ü ±â¾÷ ¹× °Ë»ç ½Ã¼³
  • º´¿ø ¹× ÀÓ»ó Äɾî

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸ÂÃãÇü ÀÇ·á ½ÃÀå

  • ¼­·Ð
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸ÂÃãÇü ÀÇ·á ½ÃÀå

  • ¼­·Ð
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸ÂÃãÇü ÀÇ·á ½ÃÀå

  • ¼­·Ð
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Amgen, Inc.
  • AstraZeneca
  • Bayer Ag
  • BIOGEN INC.
  • Eli Lilly and Company
  • Exact Sciences Corporation
  • Exagen Inc
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc.
  • Glaxosmithkline Plc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Precision Biologics, Inc.
  • QIAGEN GmbH
  • Takeda Pharmaceutical Company Limited
LSH 25.01.03

The Personalized Medicine Market was valued at USD 542.10 billion in 2023, expected to reach USD 575.50 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 852.02 billion by 2030.

Personalized medicine (PM) represents a transformative approach in healthcare, focusing on tailoring treatments to individual genetic, environmental, and lifestyle factors. Its scope encompasses genomics, pharmacogenomics, and advanced diagnostics, essential for devising precise treatment plans. The necessity of personalized medicine grows with the rising patient demand for customized therapeutic solutions, increased prevalence of chronic diseases, and advancements in omics technologies. Application areas range from oncology, where targeted therapies offer new hope for cancer patients, to cardiovascular diseases and rare genetic disorders, each benefiting significantly from this personalized approach. End-use segments include hospitals, diagnostic labs, and research institutions, all of which leverage PM to enhance treatment outcomes and operational efficiencies.

KEY MARKET STATISTICS
Base Year [2023] USD 542.10 billion
Estimated Year [2024] USD 575.50 billion
Forecast Year [2030] USD 852.02 billion
CAGR (%) 6.67%

Key factors accelerating market growth include technological advancements, investment in research and development, and favorable regulatory frameworks promoting precision medicine initiatives. However, there are challenges such as high costs of genomic sequencing, data privacy concerns, and the complexity of integrating PM into traditional healthcare practices. Nevertheless, emerging opportunities abound, such as the integration of artificial intelligence and machine learning in processing large datasets for biomarker discovery, which can enhance predictive accuracy and treatment efficacy.

Innovative research areas include the development of cost-effective sequencing technologies and the exploration of microbiome influence on pharmacogenomics. Businesses can gain a competitive edge by investing in digital health solutions that combine PM with telemedicine, offering comprehensive, personalized care remotely. Despite being a complex and fragmented landscape, the personalized medicine market offers robust growth potential. To harness these opportunities, companies should focus on strategic partnerships, technological integration, and patient-centric approaches to service delivery. The nature of the market is dynamic, evolving rapidly with technological advancements and regulatory changes, necessitating continuous innovation and adaptation for sustained business growth and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Personalized Medicine Market

The Personalized Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in biotechnology research initiatives and improved understanding of genetics
    • Surge in the adoption of personalized treatment strategies for targeting complex diseases
    • Supportive government initiatives to raise awareness for and access to personalized medicine
  • Market Restraints
    • Complexities in the implementation of personalized medicine and lack of skilled personnel
  • Market Opportunities
    • Ongoing R&D activities for improvements in personalized medicines
    • Potential for the adoption of virtual and digital strategies for personalized medicine
  • Market Challenges
    • Limited accessibility and issues related to accuracy

Porter's Five Forces: A Strategic Tool for Navigating the Personalized Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Personalized Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Personalized Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Personalized Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Personalized Medicine Market

A detailed market share analysis in the Personalized Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Personalized Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Personalized Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Personalized Medicine Market

A strategic analysis of the Personalized Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Personalized Medicine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen, Inc., AstraZeneca, Bayer Ag, BIOGEN INC., Eli Lilly and Company, Exact Sciences Corporation, Exagen Inc, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., Glaxosmithkline Plc., Illumina, Inc., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Precision Biologics, Inc., QIAGEN GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Personalized Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Personalized Medical Care, Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, and Personalized Nutrition & Wellness. The Personalized Medical Care is further studied across Health Information Technology and Telemedicine. The Personalized Medicine Diagnostics is further studied across Direct-to-consumer (DTC) Diagnostics, Esoteric Lab Services, Esoteric Lab Tests, and Genetic Testing. The Personalized Medicine Therapeutics is further studied across Genomic Medicine, Medical Devices, and Pharmaceutical. The Personalized Nutrition & Wellness is further studied across Complementary & Alternative Medicine and Retail Nutrition.
  • Based on Application, market is studied across Antiviral, Cardiology, Immunology, Neurology, Oncology, and Psychiatry.
  • Based on End Users, market is studied across Academic Research Institutes & Research Laboratories, Bio & Health Informatics Companies, Contract Research Organizations, Diagnostic Companies & Testing Facilities, and Hospitals & Clinical Care.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in biotechnology research initiatives and improved understanding of genetics
      • 5.1.1.2. Surge in the adoption of personalized treatment strategies for targeting complex diseases
      • 5.1.1.3. Supportive government initiatives to raise awareness for and access to personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities in the implementation of personalized medicine and lack of skilled personnel
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for improvements in personalized medicines
      • 5.1.3.2. Potential for the adoption of virtual and digital strategies for personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited accessibility and issues related to accuracy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing awareness about physical health and mental health owing to the adoption of personalized nutrition & wellness
    • 5.2.2. Application: Increased adoption of personalized medicine in neurology due to the need for precise treatment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Personalized Medicine Market, by Product

  • 6.1. Introduction
  • 6.2. Personalized Medical Care
    • 6.2.1. Health Information Technology
    • 6.2.2. Telemedicine
  • 6.3. Personalized Medicine Diagnostics
    • 6.3.1. Direct-to-consumer (DTC) Diagnostics
    • 6.3.2. Esoteric Lab Services
    • 6.3.3. Esoteric Lab Tests
    • 6.3.4. Genetic Testing
  • 6.4. Personalized Medicine Therapeutics
    • 6.4.1. Genomic Medicine
    • 6.4.2. Medical Devices
    • 6.4.3. Pharmaceutical
  • 6.5. Personalized Nutrition & Wellness
    • 6.5.1. Complementary & Alternative Medicine
    • 6.5.2. Retail Nutrition

7. Personalized Medicine Market, by Application

  • 7.1. Introduction
  • 7.2. Antiviral
  • 7.3. Cardiology
  • 7.4. Immunology
  • 7.5. Neurology
  • 7.6. Oncology
  • 7.7. Psychiatry

8. Personalized Medicine Market, by End Users

  • 8.1. Introduction
  • 8.2. Academic Research Institutes & Research Laboratories
  • 8.3. Bio & Health Informatics Companies
  • 8.4. Contract Research Organizations
  • 8.5. Diagnostic Companies & Testing Facilities
  • 8.6. Hospitals & Clinical Care

9. Americas Personalized Medicine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Personalized Medicine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Personalized Medicine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AstraZeneca Acquires Fusion Pharmaceuticals for Personalized Cancer Medicine
    • 12.3.2. CurifyLabs Acquires Key 3D Printing IP from Mehta Heino Industries to Advance Personalized Medicine Solutions
    • 12.3.3. Strategic Acquisition Enhances Novartis' Precision Medicine Capabilities
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen, Inc.
  • 3. AstraZeneca
  • 4. Bayer Ag
  • 5. BIOGEN INC.
  • 6. Eli Lilly and Company
  • 7. Exact Sciences Corporation
  • 8. Exagen Inc
  • 9. F. Hoffmann-La Roche Ltd
  • 10. GE HealthCare Technologies Inc.
  • 11. Glaxosmithkline Plc.
  • 12. Illumina, Inc.
  • 13. Johnson & Johnson Services, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Merck & Co., Inc.
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Precision Biologics, Inc.
  • 19. QIAGEN GmbH
  • 20. Takeda Pharmaceutical Company Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦